Volume 2, Issue 2 (9-2019)
2019, 2(2): 0-0 |
Back to browse issues page
Ethics code: IR.Medilam.REC.1398.181
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
tardeh Z. Prevalence of Metabolic Syndrome in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis study. Journal title 2019; 2 (2)
URL: http://newresearch.medilam.ac.ir/article-1-553-en.html
URL: http://newresearch.medilam.ac.ir/article-1-553-en.html
Abstract: (2384 Views)
Context: Polycystic ovary syndrome (PCOS) is an endocrinopathy with unknown pathophysiology in women of reproductive age. Several studies have been conducted to find the prevalence of metabolic syndrome(MetS) in PCOS patients but the results are different. This study conducted to find the prevalence of MetS in PCOS patients using related published data.
Method: Current systematic review and meta-analysis study conducted based on preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. Search conducted using MeSH keywords of metabolic syndrome, Polycystic ovary syndrome, prevalence in databases of PubMed, Scopus, Embase, CINAHL, Web of Science, Cochrane Library, EBSCO and Google scholar search engine and the reference list of the retrieved papers without time limitation until 2018. We used Cochran’s Q test and I2 Index to evaluate heterogeneity among studies and random model effect use to combine the results. Data analysis was performed in Stat ver 11.1.
Results: 46 studies involving 8946 patients with PCOS included the final analysis. Total heterogeneity in the current study was high (I2: 91.43%, P < 0.001). The Prevalence of MetS in PCOS patients was estimated to be 30% (95% CI: 27-33). Subgroup of analysis based on MetS diagnostic criteria resulted in estimated prevalence of 0.27% (95% CI: 0.18, 0.37), 0.30% (95% CI: 0.27, 0.34), 0.32 (95% CI: 0.25, 0.39), 0.32 (95% CI: 0.27, 0.37) and 0.24 (95% CI: 0.14, 0.34) for IDF, NECP-ATPIII, AHA NHLBI, CDS and unknown criteria respectively.
Conclusion: According to prevalence of MetS in PCOS patients, diagnosis of MetS in patients with PCOS to reduce the rate of mortality and morbidity is needed.
Method: Current systematic review and meta-analysis study conducted based on preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. Search conducted using MeSH keywords of metabolic syndrome, Polycystic ovary syndrome, prevalence in databases of PubMed, Scopus, Embase, CINAHL, Web of Science, Cochrane Library, EBSCO and Google scholar search engine and the reference list of the retrieved papers without time limitation until 2018. We used Cochran’s Q test and I2 Index to evaluate heterogeneity among studies and random model effect use to combine the results. Data analysis was performed in Stat ver 11.1.
Results: 46 studies involving 8946 patients with PCOS included the final analysis. Total heterogeneity in the current study was high (I2: 91.43%, P < 0.001). The Prevalence of MetS in PCOS patients was estimated to be 30% (95% CI: 27-33). Subgroup of analysis based on MetS diagnostic criteria resulted in estimated prevalence of 0.27% (95% CI: 0.18, 0.37), 0.30% (95% CI: 0.27, 0.34), 0.32 (95% CI: 0.25, 0.39), 0.32 (95% CI: 0.27, 0.37) and 0.24 (95% CI: 0.14, 0.34) for IDF, NECP-ATPIII, AHA NHLBI, CDS and unknown criteria respectively.
Conclusion: According to prevalence of MetS in PCOS patients, diagnosis of MetS in patients with PCOS to reduce the rate of mortality and morbidity is needed.
: Cross sectional |
Subject:
General
Received: 2019/01/25 | Accepted: 2019/02/27 | Published: 2019/09/15
Received: 2019/01/25 | Accepted: 2019/02/27 | Published: 2019/09/15
Send email to the proposal executer
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
